STUDY OF ARTIFICIAL INTELLIGENCE SOLUTION TO DETECT PROSTATE CANCER WINS MAJOR FUNDING AWARD
A study to assess an artificial intelligence solution for detecting prostate cancer has been selected from over 530 applicants as one of the first winners of the Artificial Intelligence in Health and Care Award.
The NIHR-funded award aims to accelerate evaluation of the most promising artificial intelligence technologies to meet the strategic aims set out in the NHS long term plan. Dr Adam Brentnall, Turing Fellow and Lecturer in Biostatistics at Queen Mary’s Wolfson Institute, is a joint Principal Investigator leading on statistics for the collaborative study led by Prof Hashim Ahmed from Imperial College London. The project is in collaboration with Ibex Medical Analytics, who have developed the Galen™ Prostate a CE-IVD marked deep-learning based solution for prostate cancer diagnosis in pathology. This research will receive a share of the £50m initial funding award, to investigate the clinical and cost effectiveness of the Ibex AI solution in detecting clinically important cancer in prostate biopsy slides from 600 men across six NHS hospitals, and comparing results with assessment from expert pathologists.
Dr Brentnall said: "The study will be the first to validate a type of algorithm and solution that has never been tested on a UK-based population. The results will help to determine the algorithm’s accuracy in ruling-out and detecting prostate cancer on biopsy tissue, as well as its cost effectiveness. This information will be crucial for the development of robust national clinical guidelines regarding potential use and implementation of this technology in the NHS."